The reiteration of a Buy rating and the maintenance of a $20 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors and potentially lead to a positive short-term impact on Ocuphire Pharma's stock price. The analyst's endorsement serves as a strong signal to the market about the firm's belief in the company's future prospects.